- Home
- ICCM vs CLGN Comparison
ICCM vs CLGN Comparison
Compare ICCM & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- CLGN
- Stock Information
- Founded
- ICCM 2006
- CLGN 2004
- Country
- ICCM Israel
- CLGN Israel
- Employees
- ICCM N/A
- CLGN N/A
- Industry
- ICCM
- CLGN Industrial Specialties
- Sector
- ICCM
- CLGN Health Care
- Exchange
- ICCM Nasdaq
- CLGN Nasdaq
- Market Cap
- ICCM 45.5M
- CLGN 39.1M
- IPO Year
- ICCM N/A
- CLGN N/A
- Fundamental
- Price
- ICCM $1.12
- CLGN $3.41
- Analyst Decision
- ICCM Strong Buy
- CLGN Strong Buy
- Analyst Count
- ICCM 2
- CLGN 2
- Target Price
- ICCM $2.70
- CLGN $12.50
- AVG Volume (30 Days)
- ICCM 646.4K
- CLGN 13.8K
- Earning Date
- ICCM 11-26-2024
- CLGN 11-27-2024
- Dividend Yield
- ICCM N/A
- CLGN N/A
- EPS Growth
- ICCM N/A
- CLGN N/A
- EPS
- ICCM N/A
- CLGN N/A
- Revenue
- ICCM $3,671,000.00
- CLGN $650,000.00
- Revenue This Year
- ICCM $18.61
- CLGN N/A
- Revenue Next Year
- ICCM $54.91
- CLGN $692.59
- P/E Ratio
- ICCM N/A
- CLGN N/A
- Revenue Growth
- ICCM 26.02
- CLGN N/A
- 52 Week Low
- ICCM $0.48
- CLGN $3.31
- 52 Week High
- ICCM $1.57
- CLGN $6.99
- Technical
- Relative Strength Index (RSI)
- ICCM 75.27
- CLGN 38.54
- Support Level
- ICCM $0.79
- CLGN $3.60
- Resistance Level
- ICCM $1.19
- CLGN $4.17
- Average True Range (ATR)
- ICCM 0.08
- CLGN 0.17
- MACD
- ICCM 0.03
- CLGN -0.03
- Stochastic Oscillator
- ICCM 84.44
- CLGN 14.29
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.